AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33909232 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events (TRAE)
Number of subjects: 14
Study 33909449 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) + doxorubicin, vinblastine, and dacarbazine (AVD) for four cycles
Number of subjects: 117
Study 33909449 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) + AVD
Number of subjects: 117
Study 33909588 — intervention group
Group type: EXPERIMENTAL
Intervention: Support, monitoring, and reminder technology for mild dementia
Number of subjects: 200
Study 33909588 — intervention group
Group type: EXPERIMENTAL
Intervention: Television-based assistive integrated service
Number of subjects: 200
Study 33909588 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 200
Study 33909619 — intervention group
Group type: EXPERIMENTAL
Intervention: Isothermal Recombinase Polymerase Amplification (RPA) targeting Leishmania kinetoplast DNA with lateral flow (LF) immunochromatographic strip
Number of subjects: 118
Study 33909619 — intervention group
Group type: COMPARATOR
Intervention: Standard of care routine diagnostic tests
Number of subjects: 118
Study 33909934 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib + Fulvestrant
Number of subjects: 120
Study 33909934 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (real-world cohort)
Number of subjects: 120
Study 33910089 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian tissue cryopreservation (OTC)
Number of subjects: 75
Study 33910089 — intervention group
Group type: EXPERIMENTAL
Intervention: Testicular tissue cryopreservation (TTC)
Number of subjects: 75
Study 33910154 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger right than left frontal alpha power prior to drug treatment in female patients.
Number of subjects: 100
Study 33910154 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher central left alpha power relative to the right in female non-responders.
Number of subjects: 100
Study 33910154 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower theta activity at anterior cingulate cortex (ACC) in remitters.
Number of subjects: 100
Study 33910154 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha asymmetry in women with MDD.
Number of subjects: 100
Study 33910159 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia Severity Index-3 (ISI-3)
Number of subjects: 3444
Study 33910159 — intervention group
Group type: COMPARATOR
Intervention: 7-item ISI
Number of subjects: 3444
Study 33910277 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant nivolumab plus ipilimumab
Number of subjects: 0
Study 33910277 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant immune-chemotherapy
Number of subjects: 0
Study 33910277 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab monotherapy
Number of subjects: 0
Study 33910277 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 0
Study 33910277 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant immune checkpoint inhibitor monotherapy
Number of subjects: 0
Study 33910334 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy plus eltrombopag
Number of subjects: 416
Study 33910334 — intervention group
Group type: COMPARATOR
Intervention: Immunosuppressive therapy alone
Number of subjects: 416
Study 33910334 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy with or without eltrombopag
Number of subjects: 416
Study 33910334 — intervention group
Group type: COMPARATOR
Intervention: Immunosuppressive therapy
Number of subjects: 416
Study 33910942 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 240
Study 33910968 — intervention group
Group type: EXPERIMENTAL
Intervention: Exebacase (CF-301)
Number of subjects: 0
Study 33910968 — intervention group
Group type: COMPARATOR
Intervention: S. aureus ATCC 29213
Number of subjects: 0
Study 33910968 — intervention group
Group type: COMPARATOR
Intervention: Enterococcus faecalis ATCC 29212
Number of subjects: 0
Study 33911143 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 330
Study 33911143 — intervention group
Group type: COMPARATOR
Intervention: Deferred revascularization
Number of subjects: 330
Study 33912079 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 33912079 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33912096 — intervention group
Group type: EXPERIMENTAL
Intervention: Olweus Bully/Victim Questionnaire-Revised version (OBVQ-R)
Number of subjects: 2775
Study 33912096 — intervention group
Group type: COMPARATOR
Intervention: Comparison with the School Violence between Peers Questionnaire and the Internet Experiences Questionnaire
Number of subjects: 2775
Study 33912096 — intervention group
Group type: EXPERIMENTAL
Intervention: Item Response Theory analysis
Number of subjects: 2775
Study 33912096 — intervention group
Group type: EXPERIMENTAL
Intervention: Victimization scale
Number of subjects: 2775
Study 33912096 — intervention group
Group type: EXPERIMENTAL
Intervention: Perpetration subscale
Number of subjects: 2775
Study 33912096 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential item functioning analysis by gender
Number of subjects: 2775
Study 33912102 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience intervention for chronic pain
Number of subjects: 88
Study 33912102 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 88
Study 33912178 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-35-secreting B (IL-35+B) cells
Number of subjects: 0
Study 33912178 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10-producing B (B10) cells
Number of subjects: 0
Study 33912244 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-first thrombectomy
Number of subjects: 1225
Study 33912244 — intervention group
Group type: COMPARATOR
Intervention: SR-first thrombectomy
Number of subjects: 1225
Study 33912273 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular Acupuncture
Number of subjects: 0
Study 33912273 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33912450 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized dynamic physical activity intervention
Number of subjects: 57
Study 33912461 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib (250 mg orally per day) plus Camrelizumab (200 mg intravenously every three weeks)
Number of subjects: 22
Study 33912461 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib plus Camrelizumab
Number of subjects: 22
Study 33912470 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential consolidation with pembrolizumab for four cycles followed by nab-paclitaxel for four cycles (P→A)
Number of subjects: 20
Study 33912470 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel followed by pembrolizumab (A→P)
Number of subjects: 20
Study 33912470 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent nab-paclitaxel and pembrolizumab for four cycles (AP)
Number of subjects: 20
Study 33912470 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measured by FACT-L
Number of subjects: 20
Study 33912524 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed Cord Clamping
Number of subjects: 0
Study 33912524 — intervention group
Group type: COMPARATOR
Intervention: Control (Standard Cord Clamping)
Number of subjects: 0
Study 33912651 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 600
Study 33912753 — intervention group
Group type: EXPERIMENTAL
Intervention: tolvaptan 60/30 mg daily
Number of subjects: 0
Study 33912753 — intervention group
Group type: EXPERIMENTAL
Intervention: tolvaptan
Number of subjects: 0
Study 33912799 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram+golimumab (TNF-α inhibitor)
Number of subjects: 180
Study 33912799 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram+calcium tablet+vitamin D (PKC activator)
Number of subjects: 180
Study 33912799 — intervention group
Group type: COMPARATOR
Intervention: escitalopram+placebo
Number of subjects: 180
Study 33912999 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI regimen
Number of subjects: 109
Study 33912999 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX regimen
Number of subjects: 109
Study 33912999 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of oxaliplatin
Number of subjects: 109
Study 33912999 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct conversion of NPC into SN-38
Number of subjects: 109
Study 33913006 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex decongestive physiotherapy (CDP)
Number of subjects: 27
Study 33913035 — intervention group
Group type: EXPERIMENTAL
Intervention: Debridement
Number of subjects: 15
Study 33913035 — intervention group
Group type: COMPARATOR
Intervention: Microfracture
Number of subjects: 15
Study 33913035 — intervention group
Group type: COMPARATOR
Intervention: Autologous chondrocyte implantation
Number of subjects: 15
Study 33913086 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg once daily
Number of subjects: 641
Study 33913086 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg once daily
Number of subjects: 641
Study 33913086 — intervention group
Group type: COMPARATOR
Intervention: Placebo switched to upadacitinib 15 mg once daily at week 24
Number of subjects: 641
Study 33913086 — intervention group
Group type: COMPARATOR
Intervention: Placebo switched to upadacitinib 30 mg once daily at week 24
Number of subjects: 641
Study 33913086 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 641
Study 33913086 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 641
Study 33913104 — intervention group
Group type: EXPERIMENTAL
Intervention: ACV lip patch
Number of subjects: 25
Study 33913104 — intervention group
Group type: COMPARATOR
Intervention: Placebo lip patch
Number of subjects: 25
Study 33913277 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion-Weighted MRI (DW MRI)
Number of subjects: 890
Study 33913277 — intervention group
Group type: COMPARATOR
Intervention: Mammography
Number of subjects: 890
Study 33913277 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonography
Number of subjects: 890
Study 33913277 — intervention group
Group type: COMPARATOR
Intervention: Dynamic Contrast-Enhanced MRI (DCE MRI)
Number of subjects: 890
Study 33913631 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified coronally advanced tunnel (MCAT) technique with porcine-derived acellular dermal matrix (PADM)
Number of subjects: 12
Study 33913631 — intervention group
Group type: COMPARATOR
Intervention: Connective tissue grafting (CTG)
Number of subjects: 12
Study 33913631 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pain intensity and pain duration in the first week after surgery with PADM
Number of subjects: 12
Study 33913819 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Steps intervention (includes in-person mind-body exercise classes, educational website, online mind-body videos, and pedometer with step-count feedback and goals)
Number of subjects: 0
Study 33913819 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Steps intervention
Number of subjects: 0
Study 33914096 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 min physical activity per school day during nine compulsory school years
Number of subjects: 81
Study 33914096 — intervention group
Group type: COMPARATOR
Intervention: 60 min physical activity per school week (reference group)
Number of subjects: 81
Study 33914097 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor 100 mg weekly with FLAG-Ida
Number of subjects: 14
Study 33914097 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor (60 mg, 80 mg, 100 mg weekly) with FLAG-Ida
Number of subjects: 14
Study 33914329 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil patient-controlled analgesia (RPCA)
Number of subjects: 161
Study 33914329 — intervention group
Group type: COMPARATOR
Intervention: Combined spinal-epidural analgesia (CSEA)
Number of subjects: 161
Study 33914350 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurbinectedin (3.2 mg/m)
Number of subjects: 244
Study 33914350 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) administration
Number of subjects: 244
Study 33914350 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet transfusions
Number of subjects: 244
Study 33914706 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-γ treatment
Number of subjects: 0
Study 33914706 — intervention group
Group type: COMPARATOR
Intervention: anti-PD-1 therapy
Number of subjects: 0
Study 33915374 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5 mg/d
Number of subjects: 3
Study 33915374 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 3 mg/d
Number of subjects: 3
Study 33915374 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine (overall)
Number of subjects: 3
Study 33915374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 33915943 — intervention group
Group type: EXPERIMENTAL
Intervention: Engerix-B
Number of subjects: 0
Study 33915943 — intervention group
Group type: COMPARATOR
Intervention: Sci-B-Vac
Number of subjects: 0
Study 33916077 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil-Lymphocyte Ratio (NLR) changes from baseline to Month 12
Number of subjects: 0
Study 33916077 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Lymphocyte Ratio (PLR) changes from baseline to Month 12
Number of subjects: 0
Study 33917201 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) treatment
Number of subjects: 0
Study 33917201 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 full-length (FL), p53β and p53γ protein isoforms
Number of subjects: 0
Study 33917922 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy de-escalation (ticagrelor replaced with clopidogrel)
Number of subjects: 1803
Study 33917922 — intervention group
Group type: COMPARATOR
Intervention: Standard antiplatelet therapy
Number of subjects: 1803
Study 33917922 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (APT)
Number of subjects: 1803
Study 33919763 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel Oral Liquid Formulation of 13-
Number of subjects: 0
Study 33920489 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CP) infusion
Number of subjects: 0
Study 33920489 — intervention group
Group type: COMPARATOR
Intervention: Matched propensity score analysis
Number of subjects: 0
Study 33921051 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bronchodilation monotherapy
Number of subjects: 764
Study 33921166 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic formulation
Number of subjects: 0
Study 33921527 — intervention group
Group type: EXPERIMENTAL
Intervention: Karasek questionnaire, sociodemographic questionnaire, Maslach Burnout Inventory scale, Hospital Anxiety, Depression Scale, food intake questionnaire, salivary biomarkers (cortisol, immunoglobulin A, lysozyme)
Number of subjects: 0
Study 33921867 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist (VKA)
Number of subjects: 2983
Study 33921867 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 2983
Study 33921867 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 2983
Study 33921867 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist (VKA) and Rivaroxaban
Number of subjects: 2983
Study 33922391 — intervention group
Group type: EXPERIMENTAL
Intervention: FCZ (Fluconazole)
Number of subjects: 28
Study 33922391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 33922654 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral creatine monohydrate (Cr) at a dose of 2 × 7 g per day for 2 months in conjunction with ongoing therapies
Number of subjects: 0
Study 33922654 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral creatine monohydrate (Cr) at a dose of 2 × 3-5 g per day for 3-6 months (proposed future study)
Number of subjects: 0
Study 33922654 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation as monotherapy or in conjunction with metformin (future potential use)
Number of subjects: 0
Study 33923628 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolised vaccination with MVA85A
Number of subjects: 2
Study 33924960 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma biomarkers (p-tau, NfL, Aβ)
Number of subjects: 90
Study 33925513 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer-measured daily step counts (mean 10699.8 steps)
Number of subjects: 2524
Study 33925513 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer-measured daily step counts
Number of subjects: 2524
Study 33926171 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation ablation
Number of subjects: 5000000
Study 33926171 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial flutter ablation
Number of subjects: 5000000
Study 33926412 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-management camp followed by a community intervention (10-week program of weekly lifestyle education and physical activity sessions)
Number of subjects: 300
Study 33926412 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-management camp
Number of subjects: 300
Study 33926412 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle education and activity phase
Number of subjects: 300
Study 33926431 — intervention group
Group type: EXPERIMENTAL
Intervention: European countries
Number of subjects: 0
Study 33926431 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-European countries
Number of subjects: 0
Study 33926503 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchful waiting
Number of subjects: 166
Study 33926503 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment indicated (surgery or targeted systemic therapy)
Number of subjects: 166
Study 33926577 — intervention group
Group type: EXPERIMENTAL
Intervention: eScreening
Number of subjects: 0
Study 33926577 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent implementation strategy (MCIS)
Number of subjects: 0
Study 33926577 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual factors
Number of subjects: 0
Study 33926577 — intervention group
Group type: COMPARATOR
Intervention: Current screening methods (control)
Number of subjects: 0
Study 33926797 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon nanoparticles (CNs) injection (0.3 mL) into the fusion node prior to NAC.
Number of subjects: 110
Study 33926914 — intervention group
Group type: EXPERIMENTAL
Intervention: MORAb-202 (0.3 to 1.2 mg/kg intravenously once every three weeks)
Number of subjects: 22
Study 33927105 — intervention group
Group type: EXPERIMENTAL
Intervention: HPI algorithm using noninvasive ABP measurements at an alarm threshold of 85
Number of subjects: 507
Study 33927105 — intervention group
Group type: EXPERIMENTAL
Intervention: HPI algorithm using noninvasive ABP measurements at an alarm threshold of 75
Number of subjects: 507
Study 33927105 — intervention group
Group type: COMPARATOR
Intervention: HPI algorithm using invasive ABP measurements
Number of subjects: 507
Study 33927108 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation sequencing (NGS)
Number of subjects: 0
Study 33927586 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile chat-based support plus nicotine replacement therapy sampling (NRT-S)
Number of subjects: 119
Study 33927586 — intervention group
Group type: COMPARATOR
Intervention: General smoking cessation text messages
Number of subjects: 119
Study 33927680 — intervention group
Group type: EXPERIMENTAL
Intervention: Penumbra SMART COIL System
Number of subjects: 0
Study 33927689 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotitrating Bilevel Positive Airway Pressure (ABPAP)
Number of subjects: 0
Study 33927689 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 33927885 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifelong endurance athletes
Number of subjects: 600
Study 33927885 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-onset endurance athletes
Number of subjects: 600
Study 33927885 — intervention group
Group type: COMPARATOR
Intervention: Healthy non-athletes
Number of subjects: 600
Study 33928400 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET/CT
Number of subjects: 930
Study 33928400 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow biopsy (BMB)
Number of subjects: 930
Study 33928414 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33928466 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 0
Study 33928466 — intervention group
Group type: EXPERIMENTAL
Intervention: YTHDF1 reintroduction via BBB-crossing viral delivery system
Number of subjects: 0
Study 33928466 — intervention group
Group type: COMPARATOR
Intervention: Prolonged anesthesia in children
Number of subjects: 0
Study 33928713 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced MARVEL 2 algorithm (VDD pacing mode)
Number of subjects: 73
Study 33928713 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced MARVEL 2 algorithm (VVI-40 mode)
Number of subjects: 73
Study 33928713 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced MARVEL 2 algorithm
Number of subjects: 73
Study 33929089 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib
Number of subjects: 0
Study 33929089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33929327 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth tool for self-management strategies, accessed for 3 months.
Number of subjects: 16
Study 33929327 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth tool after 12 months of access.
Number of subjects: 16
Study 33929327 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth tool usage factors.
Number of subjects: 16
Study 33929327 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy measured by the Communicative and Critical Health Literacy Scale.
Number of subjects: 16
Study 33929337 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Partner [Téfal]
Number of subjects: 153
Study 33929337 — intervention group
Group type: EXPERIMENTAL
Intervention: DietPack [Terraillon]
Number of subjects: 153